USPTO Patent Application for ABHD6 Antagonist Drug
Summary
The USPTO has published a patent application filed by ONO Pharmaceutical Co., Ltd. for a novel ABHD6 antagonist drug. The application details a compound with potential therapeutic applications for diseases associated with ABHD6 activity.
What changed
This document is a USPTO patent application (US20260083735A1) filed by ONO Pharmaceutical Co., Ltd. on September 29, 2023. The application describes a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, which exhibits ABHD6 inhibitory activity. This compound is intended for use as an active ingredient in pharmaceuticals for the prevention and/or treatment of diseases associated with ABHD6.
As this is a patent application, it does not impose immediate compliance obligations on regulated entities. However, it signifies potential future developments in drug discovery within the pharmaceutical sector. Companies involved in related research and development may wish to monitor the progress of this patent application and similar innovations in the field of ABHD6 inhibitors.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ABHD6 ANTAGONIST
Application US20260083735A1 Kind: A1 Mar 26, 2026
Assignee
ONO PHARMACEUTICAL CO., LTD.
Inventors
Atsushi YOSHIDA, Ryuichi HYAKUTAKE, Nozomu NAGASHIMA, Ryosuke MISU, Shohei MORI
Abstract
A drug is provided, which contains, as an active ingredient, a compound having ABHD6 inhibitory activity in prevention and/or treatment of a disease associated with ABHD6. A compound represented by general formula (I) or a pharmaceutically acceptable salt thereof has ABHD6 inhibitory activity and therefore is useful as a pharmaceutical ingredient having potent ABHD6 inhibitory activity in the prevention and/or treatment of a disease associated with ABHD6: in which all symbols represent the same meaning as the symbols described in the specification.
CPC Classifications
A61K 31/5025 A61K 31/167 A61K 31/501 A61K 45/06 A61P 25/22 A61P 25/24 A61P 29/00 C07D 409/14 C07D 417/14 C07D 495/04 C07D 513/04 C07D 519/00
Filing Date
2023-09-29
Application No.
19113663
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.